Lilly posts pro forma on ImClone deal

Eli Lilly expects its combination with ImClone to deliver $15.5 billion in revenues for the nine months ended Sept. 30 and a combined EPS of 1.21, which because of acquisition costs and interest expenses is some 20 cents per share less than Lilly would have produced on its own. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.